Inhibitor Therapeutics, Inc. INTI
We take great care to ensure that the data presented and summarized in this overview for Inhibitor Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in INTI
Top Purchases
Top Sells
About INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Insider Transactions at INTI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Ronald E Osman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
50,000
+0.21%
|
-
|
|
Apr 01
2024
|
Samuel P Sears Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+4.24%
|
-
|
|
Apr 01
2024
|
Michelle Yanez Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+5.28%
|
-
|
|
Apr 01
2024
|
Michael Allen Jerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+38.34%
|
-
|
|
Aug 11
2023
|
Ronald E Osman Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+0.11%
|
-
|
|
May 05
2023
|
James A Mcnulty CHIEF FINANCIAL OFFICER |
BUY
Other acquisition or disposition
|
Indirect |
20,101,057
+43.51%
|
-
|
|
May 05
2023
|
James A Mcnulty CHIEF FINANCIAL OFFICER |
BUY
Other acquisition or disposition
|
Direct |
398,135
+29.62%
|
-
|
|
May 05
2023
|
James A Mcnulty CHIEF FINANCIAL OFFICER |
SELL
Other acquisition or disposition
|
Indirect |
79,627,069
-100.0%
|
-
|
|
May 05
2023
|
Michelle Yanez Director |
BUY
Other acquisition or disposition
|
Direct |
796,271
+49.86%
|
-
|
|
Jan 15
2021
|
Mayne Pharma Ventures Pty LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
2,240,488
+1.09%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 200K shares |
|---|